310 related articles for article (PubMed ID: 27555605)
41. Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy.
Kazansky Y; Cameron D; Mueller HS; Demarest P; Zaffaroni N; Arrighetti N; Zuco V; Kuwahara Y; Somwar R; Ladanyi M; Qu R; de Stanchina E; Dela Cruz FS; Kung AL; Gounder MM; Kentsis A
Cancer Discov; 2024 Jun; 14(6):965-981. PubMed ID: 38315003
[TBL] [Abstract][Full Text] [Related]
42. Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program.
Houghton PJ; Gorlick R; Kolb EA; Lock R; Carol H; Morton CL; Keir ST; Reynolds CP; Kang MH; Phelps D; Maris JM; Billups C; Smith MA
Pediatr Blood Cancer; 2012 Feb; 58(2):191-9. PubMed ID: 21337679
[TBL] [Abstract][Full Text] [Related]
43. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.
Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Wu J; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Lyalin D
Pediatr Blood Cancer; 2014 Aug; 61(8):1493-6. PubMed ID: 24664981
[TBL] [Abstract][Full Text] [Related]
44. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Morschhauser F; Tilly H; Chaidos A; McKay P; Phillips T; Assouline S; Batlevi CL; Campbell P; Ribrag V; Damaj GL; Dickinson M; Jurczak W; Kazmierczak M; Opat S; Radford J; Schmitt A; Yang J; Whalen J; Agarwal S; Adib D; Salles G
Lancet Oncol; 2020 Nov; 21(11):1433-1442. PubMed ID: 33035457
[TBL] [Abstract][Full Text] [Related]
45. Targeting EZH2 Enhances Antigen Presentation, Antitumor Immunity, and Circumvents Anti-PD-1 Resistance in Head and Neck Cancer.
Zhou L; Mudianto T; Ma X; Riley R; Uppaluri R
Clin Cancer Res; 2020 Jan; 26(1):290-300. PubMed ID: 31562203
[TBL] [Abstract][Full Text] [Related]
46. Tazemetostat for the treatment of multiple types of hematological malignancies and solid tumors.
Marsh S; Jimeno A
Drugs Today (Barc); 2020 Jun; 56(6):377-387. PubMed ID: 32525136
[TBL] [Abstract][Full Text] [Related]
47. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
48. Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.
Carol H; Morton CL; Gorlick R; Kolb EA; Keir ST; Reynolds CP; Kang MH; Maris JM; Billups C; Smith MA; Houghton PJ; Lock RB
Pediatr Blood Cancer; 2010 Dec; 55(7):1329-37. PubMed ID: 20740623
[TBL] [Abstract][Full Text] [Related]
49. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
Smith MA; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Morton CL; Wu J; Smith PG; Yu J; Houghton PJ
Pediatr Blood Cancer; 2012 Aug; 59(2):246-53. PubMed ID: 22012946
[TBL] [Abstract][Full Text] [Related]
50. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives.
Simeone N; Frezza AM; Zaffaroni N; Stacchiotti S
Future Oncol; 2021 Apr; 17(10):1253-1263. PubMed ID: 33289402
[TBL] [Abstract][Full Text] [Related]
51. Initial testing of lenalidomide by the pediatric preclinical testing program.
Reynolds CP; Kang MH; Keir ST; Gorlick R; Kolb EA; Lock R; Maris JM; Carol H; Morton CL; Billups CA; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2011 Oct; 57(4):606-11. PubMed ID: 21360651
[TBL] [Abstract][Full Text] [Related]
52. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
Zhou B; Liang X; Mei H; Qi S; Jiang Z; Wang A; Zou F; Liu Q; Liu J; Wang W; Hu C; Chen Y; Wang Z; Wang B; Wang L; Liu J; Liu Q
J Med Chem; 2021 Oct; 64(20):15170-15188. PubMed ID: 34664960
[TBL] [Abstract][Full Text] [Related]
53. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
Lue JK; Amengual JE
Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
[TBL] [Abstract][Full Text] [Related]
54. Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2).
Ma L; Zhang X; Wang Z; Huang L; Meng F; Hu L; Chen Y; Wei J
Curr Cancer Drug Targets; 2019; 19(9):729-741. PubMed ID: 30747066
[TBL] [Abstract][Full Text] [Related]
55. Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program.
Kurmasheva RT; Kurmashev D; Reynolds CP; Kang M; Wu J; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921800
[TBL] [Abstract][Full Text] [Related]
56. Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma.
Mondello P; Ansell SM
Expert Opin Pharmacother; 2022 Feb; 23(3):295-301. PubMed ID: 34904909
[TBL] [Abstract][Full Text] [Related]
57. Initial testing of topotecan by the pediatric preclinical testing program.
Carol H; Houghton PJ; Morton CL; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Maris JM; Keir ST; Watkins A; Smith MA; Lock RB
Pediatr Blood Cancer; 2010 May; 54(5):707-15. PubMed ID: 20017204
[TBL] [Abstract][Full Text] [Related]
58. Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.
Gorlick R; Kolb EA; Houghton PJ; Morton CL; Neale G; Keir ST; Carol H; Lock R; Phelps D; Kang MH; Reynolds CP; Maris JM; Billups C; Smith MA
Pediatr Blood Cancer; 2012 Dec; 59(7):1266-74. PubMed ID: 22315240
[TBL] [Abstract][Full Text] [Related]
59. Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program.
Kang MH; Reynolds CP; Kolb EA; Gorlick R; Carol H; Lock R; Keir ST; Maris JM; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2016 Oct; 63(10):1744-52. PubMed ID: 27238606
[TBL] [Abstract][Full Text] [Related]
60. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Billups CA; Hawthorne T; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 Oct; 61(10):1816-21. PubMed ID: 24912408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
